Nurittin Ardic

Dr. Nurittin Ardic

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in Microbiological Research
Verified
Journal Article
Closed access
NANurittin Ardic
Nurittin Ardic
BSBaris Sareyyupoglu
Baris Sareyyupoglu
MOMustafa Ozyurt
Mustafa Ozyurt
THTuncer Haznedaroglu
Tuncer Haznedaroglu
UIUğur Ilga
Uğur Ilga

1 September 2005 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
NANurittin Ardic
Nurittin Ardic
MOM Ozyurt
M Ozyurt
BSB Sareyyupoglu
B Sareyyupoglu
THT Haznedaroglu
T Haznedaroglu

25 August 2025 in British Journal of Hospital Medicine
Verified
Journal Article
Closed access
NANurittin Ardic
Nurittin Ardic
RDRasit Dinc
Rasit Dinc
The integration of artificial intelligence (AI) in healthcare offers the potential to play a critical role in reshaping clinical practice. However, it also brings regulatory, ethical, implementation, social, and technical challenges that healthcare systems must overcome. It is necessary for the responsible parties in AI applications to be well defined by the regulations. To create standards that encourage innovation and address ethical and security concerns, collaboration between policymakers, AI developers and healthcare providers has a vital role. In this review, it was presented an overview of the current regulatory landscape for AI in healthcare, focusing primarily on frameworks in the European Union (EU), the United States (USA), and the United Kingdom (UK), which are leading countries in this regard. The review also emphasized the challenges that need to be addressed.

5 February 2026 in Cells
Verified
Journal Article
Open access
PDF file
RDRasit Dinc
Rasit Dinc
NANurittin Ardic
Nurittin Ardic
Exosomes and other extracellular vesicles (EVs) carry microRNAs, proteins, and lipids that reflect cardiovascular pathophysiology and can enable minimally invasive biomarker discovery. However, EV datasets are highly dimensional and heterogeneous, strongly influenced by pre-analytic variables and non-standardized isolation/characterization workflows, limiting reproducibility across studies. Artificial intelligence (AI), including machine learning (ML), deep learning (DL), and network-based approaches, can support EV biomarker development by integrating multi-omics profiles with clinical metadata. These approaches enable feature selection, disease subtyping, and interpretable model development. Among the AI approaches evaluated, ensemble methods (Random Forest, gradient boosting) demonstrate the most consistent performance for EV biomarker classification (AUC 0.80–0.92), while graph neural networks (GNNs) are particularly promising for path integration but require larger validation cohorts. Evolutionary neural networks applied to EV morphological features yield comparable discrimination but face interpretability challenges for clinical use. Current studies report promising discrimination performance for selected EV-derived panels in acute myocardial infarction and heart failure. However, most evidence remains exploratory, based on small cohorts (n < 50) and limited external validation. For clinical implementation, EV biomarkers need direct comparison against established standards (high-sensitivity troponin and natriuretic peptides), supported by locked-in assay plans, and validation in multicenter cohorts using MISEV-aligned protocols and transparent AI reporting practices. Through a comprehensive, integrative, and comparative analysis of AI methodologies for EV biomarker discovery, together with explicit criteria for reproducibility and translational readiness, this review establishes a practical framework to advance exosomal diagnostics from exploratory research toward clinical implementation.

14 July 2016 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
MAMustafa Aksoy
Mustafa Aksoy
NDNebiye YENTUR DONI
Nebiye YENTUR DONI
HOHatice Uce Ozkul
Hatice Uce Ozkul
YYYavuz Yesilova
Yavuz Yesilova
NANurittin Ardic
Nurittin Ardic
Abhay SatoskarAbhay Satoskar
Abhay Satoskar
Cutaneous leishmaniasis (CL) is a major public health concern in Turkey and Sanliurfa represents the most endemic city in Turkey. Although children are most commonly affected by CL, detailed studies of pediatric CL in Turkey are lacking. In this report we retrospectively evaluated clinical and epidemiological data of 8786 pediatric CL cases, and how children respond to antimonial therapy. CL was observed most frequently in children between 6–10 years old. Interestingly this group showed shorter duration of disease and smaller lesions compared to 0–5 year and 11–15 year old groups. Females were more affected in all groups. Lesion localization and types varied among groups, with 0–5 year old presenting head/neck and mucosal lesions, and more often suffered from recidivans type, this could be associated to the longest duration of the disease in this group. Eleven-15 year old group showed fewer lesions in the head/neck but more generalized lesions. Evaluation of treatment response revealed that intra-lesional treatment was preferred over intramuscular treatment. However, 0–5 year old received intramuscular treatment more often than the other groups. Furthermore, the majority of 0–5 year old group which received intra-lesional treatment did not received subsequent intra-lesional cycles, as did children in the range of 6–15 years old. We report an increase in pediatric CL patients within the last four years. Analysis of pediatric CL patients by age revealed significant differences in CL progression. The data suggest that children between 0–5 years old responded better than other groups to intralesional treatment, since they received more often a single cycle of IL treatment, although follow up observation is required since they were more prone to develop recidivans. Eleven-15 year old patients comprise the largest percentage of patients receiving two or three cycles of intralesional treatment, suggesting that this group did not respond efficiently to intralesional treatment and highlighting the need for more effective therapeutic strategies against CL. In this study, 8786 pediatric (0-15years old) cutaneous leishmaniasis (PCL) patients were retrospectively evaluated for the epidemiological and clinical characteristics. From the records of PCL patients, we focused on the patients' age, gender, lesion type and location, diameter, number and duration of the lesions, and the treatment given. Of the patients, 4050 (46·1%) were males and 4736 (53·90%) were females, with a mean age of 7·52 years (range 0–15 years). Mean lesion diameter was 12·77±0·11 mm (range 1-100mm), while the average lesion duration and the number of lesions was 8·58±0·21 weeks and 1·76±0·01, respectively. The area most involved in the lesions of PCL patients was the head and neck region at a rate of 32·55% (n = 2230). The most (78·79%) of the PCL patients who received intralesional pentavalent antimonial therapy responded to the first cycle of treatment. It was observed that the PCL patients who applied systemic pentavalent antimonial therapy, resistant to intralesional pentavalent antimonial therapy, were completely recovered. We believe that this study will contribute to clinicians to evaluate the clinical features and therapy choice of pediatric CL patients.

3 February 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
NANurittin Ardic
Nurittin Ardic
RDRasit Dinc
Rasit Dinc
Stroke remains a leading cause of death and disability worldwide, and inflammation is increasingly recognized as a key driver of acute injury and secondary neurodegeneration. Among post-stroke immune mediators, neutrophil extracellular traps (NETs) have emerged as critical amplifiers of thromboinflammation and cerebrovascular injury. Parallel developments highlight microglia and infiltrating macrophages as key regulators of sterile inflammation in ischemic stroke (IS), intracerebral hemorrhage (ICH), and subarachnoid hemorrhage (SAH). However, the bidirectional interaction between NETs and microglia/macrophages has not been comprehensively analyzed despite its translational importance. This review describes the mechanistic pathways by which NET components activate microglial pattern recognition receptors, triggering inflammasome activation, inflammatory signaling cascades, and cytokine release. Activated microglia, in turn, promote neutrophil recruitment and NETosis, creating a self-reinforcing cycle. Evidence from ischemic and hemorrhagic stroke demonstrates how NET-microglia interactions lead to neurovascular complications such as blood-brain barrier disruption, microvascular dysfunction, and neuronal injury. We examine therapeutic strategies targeting NET formation and destruction, microglial modulation, and combination approaches to interrupt this inflammatory axis. We highlight novel biomarker and imaging approaches that may enable personalized immunotherapy. Together, these strategies position the NET-microglia/macrophage axis as a promising immunomodulatory target in ischemic and hemorrhagic stroke, offering new avenues for precision therapy development.